REGENXBIO Publishes Data from Ongoing Preclinical Studies of NAV® Gene Therapy in Neurodegenerative Diseases
September 13 2016 - 7:00AM
REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company
focused on the development, commercialization and licensing of
recombinant adeno-associated virus (AAV) gene therapy based on its
proprietary NAV® Technology Platform, today provided an update on
the recent publication of data from ongoing preclinical studies of
NAV Gene Therapy for the treatment of Mucopolysaccharidosis Type I
(MPS I) and Mucopolysaccharidosis Type II (MPS II).
“We are pleased to share additional positive preclinical
results, which were generated by our development partners at the
University of Pennsylvania, on the potential of our NAV Technology
Platform in MPS I and MPS II,” said Kenneth T. Mills, President and
Chief Executive Officer of REGENXBIO. “These results support our
long-term clinical development plans and our mission of utilizing
NAV gene therapies to improve the lives of patients suffering from
severe neurodegenerative diseases.”
RGX-111 for the treatment of MPS
I
Data from a preclinical study of RGX-111 for the treatment of
MPS I in a canine model were published online in July 2016 in the
journal Molecular Genetics and Metabolism. RGX-111 uses the NAV
AAV9 vector to deliver the human α-l-iduronidase (IDUA) gene to the
central nervous system (CNS).
The results demonstrate dose-dependent expression of IDUA and
correction of disease pathology in the brain, as well as reduction
in spinal cord compression after a single administration of NAV
AAV9 vectors expressing IDUA. These data are expected to help
establish the minimum effective dose for REGENXBIO’s planned
first-in-human studies.
The study, titled “Neonatal tolerance induction enables accurate
evaluation of gene therapy for MPS I in a canine model,” is
available online at:
http://www.mgmjournal.com/article/S1096-7192(16)30105-6/abstract.
REGENXBIO expects to submit an Investigational New Drug (IND)
application to the U.S. Food and Drug Administration (FDA) and a
Clinical Trial Application (CTA) with Health Canada for a
Phase I/II clinical trial of RGX-111 in the first half of 2017.
RGX-111 has been granted both orphan drug designation and rare
pediatric disease designation by the FDA.
RGX-121 for the treatment of MPS
II
Data from a preclinical study of RGX-121 for the treatment of
MPS II in a mouse model were published online in August 2016 in the
journal Human Gene Therapy. RGX-121 uses the NAV AAV9 vector to
deliver the human iduronate-2-sulfatase (IDS) gene to the CNS.
The results demonstrate dose-dependent expression of IDS and
correction of disease pathology in the brain after a single
administration of NAV AAV9 vectors expressing IDS. Levels of IDS in
the brain tissue, cerebrospinal fluid (CSF), and serum all
approached or exceeded normal levels. The treated mice also
demonstrated improvement in long-term memory in a novel object
recognition test, as well as evidence of correction of disease in
the liver and heart.
The study, titled “Delivery of an adeno-associated virus vector
into CSF attenuates central nervous system disease in
mucopolysaccharidosis type II mice,” is available online at:
http://online.liebertpub.com/doi/abs/10.1089/hum.2016.101.
REGENXBIO expects to submit an IND to the FDA for a Phase I/II
clinical trial of RGX-121 in the first half of 2017. RGX-121 has
been granted both orphan drug designation and rare pediatric
disease designation by the FDA.
About REGENXBIO
REGENXBIO is a leading biotechnology company focused on the
development, commercialization and licensing of recombinant
adeno-associated virus (AAV) gene therapy. REGENXBIO's NAV®
Technology Platform, a proprietary AAV gene delivery platform,
consists of exclusive rights to more than 100 novel AAV vectors,
including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO's mission is to
transform the lives of patients suffering from severe diseases with
significant unmet medical need by developing and commercializing in
vivo gene therapy products based on REGENXBIO's NAV Technology
Platform. REGENXBIO seeks to accomplish this mission through a
combination of internal development efforts and third-party NAV
Technology Platform licensees. As of June 30, 2016, REGENXBIO's NAV
Technology Platform was being applied in the development of 29
product candidates for a variety of diseases, including five
internally developed candidates and 24 partnered candidates
developed by REGENXBIO's licensees.
Forward Looking Statements
This press release contains "forward-looking statements," within
the meaning of the Private Securities Litigation Reform Act of
1995, regarding, among other things, REGENXBIO's research,
development and regulatory plans for its gene therapy treatments,
including RGX-111 and RGX-121. Such forward-looking statements are
based on current expectations and involve inherent risks and
uncertainties, including factors that could cause actual results to
differ materially from those projected by such forward-looking
statements. All of REGENXBIO’s development timelines could be
subject to adjustment depending on recruitment rate, regulatory
agency review and other factors that could delay the initiation and
completion of clinical trials. Meaningful factors which could cause
actual results to differ include, but are not limited to, the
timing of enrollment, commencement and completion of REGENXBIO's
clinical trials; the timing and success of preclinical studies and
clinical trials conducted by REGENXBIO, its development partners
and its NAV® Technology Licensees; the ability to obtain and
maintain regulatory approval to conduct clinical trials and to
commercialize REGENXBIO's product candidates, and the labeling for
any approved products; the scope, progress, expansion, and costs of
developing and commercializing REGENXBIO's product candidates;
REGENXBIO's ability to obtain and maintain intellectual property
protection for our product candidates and technology; trends and
challenges in REGENXBIO's business and the markets in which
REGENXBIO operates; REGENXBIO's ability to attract or retain key
personnel; the size and growth of the potential markets for
REGENXBIO's product candidates and the ability to serve those
markets; the rate and degree of market acceptance of any of
REGENXBIO's product candidates; REGENXBIO's ability to establish
and maintain development partnerships, including those with NAV
Technology Licensees; REGENXBIO's expenses and revenue, the
sufficiency of REGENXBIO's cash resources and needs for additional
financing, regulatory developments in the United States and foreign
countries, as well as other factors discussed in the "Risk Factors"
and "Management's Discussion and Analysis of Financial Condition
and Results of Operations" sections of REGENXBIO's Annual Report on
Form 10-K for the year ended December 31, 2015 and Quarterly Report
on Form 10-Q for the quarter ended June 30, 2016, which are
available on the SEC's website at www.sec.gov. In addition to the
risks described above and in REGENXBIO's filings with the SEC,
other unknown or unpredictable factors also could affect
REGENXBIO's results. There can be no assurance that the actual
results or developments anticipated by REGENXBIO will be realized
or, even if substantially realized, that they will have the
expected consequences to, or effects on, REGENXBIO. Therefore, no
assurance can be given that the outcomes stated in such
forward-looking statements and estimates will be achieved.
All forward-looking statements contained in this press release
are expressly qualified by the cautionary statements contained or
referred to herein. REGENXBIO cautions investors not to
rely too heavily on the forward-looking
statements REGENXBIO makes or that are made on its
behalf. These forward-looking statements speak only as of the date
of this press release (unless another date is
indicated). REGENXBIO undertakes no obligation, and
specifically declines any obligation, to publicly update or revise
any such forward-looking statements, whether as a result of new
information, future events or otherwise.
CONTACT:
Investors
Elizabeth Broder, 646-378-2945
ebroder@troutgroup.com
Media
Laura Bagby, 312-448-8098
lbagby@6degreespr.com
REGENXBIO (NASDAQ:RGNX)
Historical Stock Chart
From Mar 2024 to Apr 2024
REGENXBIO (NASDAQ:RGNX)
Historical Stock Chart
From Apr 2023 to Apr 2024